

Bactiguard received EU grant for air bridge

Bactiguard has received an EU grant of SEK 1.4 million for the air bridge that was established for the transport of protective equipment and disinfectants from Asia to Europe in connection with the outbreak of the COVID-19 pandemic. The grant has in full been transferred to Bactiguard's partner Svenskt Industriflyg as compensation for their additional costs.

The rapid spread of the COVID-19 pandemic in the spring led to a large number of countries closing their borders and the regular transport capacity disappeared when the airlines cancelled routes and departures. This caused major consequences for the healthcare sector and the need for medical equipment became urgent. For this reason, Bactiguard, together with Svenskt Industriflyg, quickly established an air bridge that ensured continued transports of protective equipment and disinfectants.

The cost of the private air bridge has been high and Bactiguard therefore applied for EU funding under the program established for transport of medical devices to alleviate the COVID-19 crisis.

The application was approved just before the end of last year and has now been paid out. The grant covers far from the entire additional cost for the air bridge and according to the agreement reached when it was established, the whole grant has been transferred to Svenskt Industriflyg.

For further information, please contact:

Gabriella Caracciolo, CFO and deputy CEO, mobile +46 72 141 62 49



Bactiguard received an EU grant of a total of SEK 1.4 million for the air bridge that was established for the transport of protective equipment and disinfectants from Asia to Europe in connection with the outbreak of the COVID-19 pandemic.

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes Hydrocyn[®] aqua, a non-alcoholic product line for wound care and disinfection. Hydrocyn effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.

Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com